Keytruda

Selected form

Pembrolizumab

Treatment option: Malignant Melanoma, Carcinoma, Lymphoma, Hodgkin Lymphoma, Cancer, Urothelial Carcinoma, Chemotherapy

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Keytruda

Property	Description
Active ingredient	Pembrolizumab
Form	Solution for intravenous infusion; Solution for subcutaneous injection
Pharmacological class	Immune Checkpoint Inhibitor; Antineoplastic Agent
General Purpose	Restoring the body’s anti-tumor immune response
Origin	Biologic therapy (Humanized Monoclonal Antibody)

Keytruda is a modern, prescription-only medication developed by Merck and classified as an Immune Checkpoint Inhibitor. Its active ingredient, Pembrolizumab, is a humanized monoclonal antibody that is engineered using recombinant DNA technology. This identity places the drug within a highly specialized class of antineoplastic agents intended for systemic treatment by modulating the immune system.

Defining the PD-1 Blocking Agent

Pembrolizumab is an antibody that works by selectively blocking the Programmed Death Receptor-1 (PD-1) protein on T-cells, thereby promoting T-cell activity. This mechanism is key to its classification as a PD-1 blocking antibody. Its function involves preventing the PD-1 receptor, which normally acts as an inhibitory checkpoint on the T-cell, from being activated by ligands like PD-L1 and PD-L2 produced by tumor cells. This pharmacological action is characterized by the potentiation of T-cell responses through targeted blockade. This means the therapy helps the body's primary immune cells overcome a key evasive tactic used by cancer.

Composition and Delivery Forms

The medication is supplied as both a solution for intravenous infusion and a combination solution for subcutaneous injection, offering two primary methods of delivery. The standard formulation is administered via intravenous infusion, often supplied as a lyophilized powder requiring reconstitution. The alternative solution for subcutaneous injection is a distinctive combination product that contains Pembrolizumab co-formulated with the enzyme Berahyaluronidase alfa-pmph. This auxiliary component facilitates the efficient dispersion and absorption of the large monoclonal antibody molecule within the subcutaneous tissue.

General Purpose of Immune Checkpoint Blockade

The overall therapeutic goal of Keytruda is to reverse the process of immune evasion utilized by various tumors and enable the body to mount a potent anti-tumor immune response. By modulating the PD-1/PD-L1 pathway, the drug is intended to alter the patient's systemic immune response to malignancy. This modulation allows the immune system to execute its natural function of identifying and destroying malignant cells without exerting a direct cytotoxic effect on cells.

Regulatory References

NIH DailyMed for KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph)

What side effects are possible with Keytruda?

Possible side effects and safety information

Adverse reaction scope Keytruda's safety profile is defined by Immune-Mediated Adverse Reactions (IMARs), which are potentially severe or fatal events that can affect virtually any organ system, as noted in official regulatory documents. These are the most clinically significant safety concern associated with this class of therapy.

Frequency Classification and Organ Systems

The most commonly listed adverse reactions are classified as Very Common (ge 1/10) and include fatigue, musculoskeletal pain, pruritus (itching), diarrhea, and decreased appetite. Other frequently noted effects are categorized under specific System-Organ Classes, such as Endocrine Disorders (e.g., hypothyroidism, adrenal insufficiency), Gastrointestinal Disorders (e.g., colitis), and Respiratory Disorders (e.g., pneumonitis).

Serious Adverse Reactions

Serious adverse reactions explicitly documented in official regulatory sources include immune-mediated pneumonitis, colitis, hepatitis, nephritis, and endocrinopathies. Less common, but serious, IMARs include Type 1 diabetes mellitus and myocarditis. The labeling also documents severe or life-threatening infusion-related reactions and complications when used in patients with a history of allogeneic hematopoietic stem cell transplantation (HSCT).

Safety-Related Patterns and Limitations

The regulatory safety notes state that IMARs can occur at any time during treatment or even after discontinuation of the therapy. The drug is contraindicated in individuals with a history of severe hypersensitivity to the active substance (pembrolizumab). Official data indicate that older adults (ge 65 years) may have a higher incidence of certain adverse reactions, such as diarrhea and colitis, and the drug can cause fetal harm (embryofetal toxicity) when administered during pregnancy, based on its mechanism.

Connection to the overall safety profile

The official safety structure is centered on the risk of Immune-Mediated Adverse Reactions, reflecting the known effects of modulating the immune system, and outlines specific organ systems affected by this action. This high-level classification provides a formal, medically grounded summary of the drug's safety characteristics and documented constraints.

Overdose and Emergency Response

Keytruda (Pembrolizumab) Overdose and When to Seek Help

The official regulatory prescribing information for Keytruda addresses the potential for overdosage by focusing on mandatory emergency actions and general supportive measures. Regulatory sources, including those from the FDA and EMA, state that no specific symptoms, clinical signs, or laboratory abnormalities resulting from an acute, excessive dose have been formally documented. Due to this lack of a defined acute overdose syndrome, specific dose-related or population-specific considerations are not detailed in the official overdosage sections.

When Immediate Medical Help Is Required

Seek immediate medical attention upon the suspicion or recognition of an overdosage.
The primary regulatory instruction is to notify a qualified healthcare professional immediately for necessary assessment and management.

Official Overdose Management Statements

No specific antidote is known for Pembrolizumab.
Management of a suspected overdosage is limited to the administration of symptomatic treatment and general supportive measures.
Requires close observation of the patient by a healthcare professional for an appropriate period to monitor for potential adverse reactions.

The overall overdose profile is therefore defined by the regulatory requirement for immediate intervention and non-specific supportive care, rather than a unique set of documented manifestations.

Therapeutic Uses of Keytruda

Keytruda (Pembrolizumab) is used in oncology to manage the disease and provide supportive care in contexts involving heightened systemic burden. It is commonly employed to address a wide range of solid and hematologic tumors, focusing on achieving long-term condition stability. The medication is considered relevant for advanced and metastatic conditions, particularly Melanoma, Non-Small Cell Lung Cancer (NSCLC), Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), and Classical Hodgkin Lymphoma (cHL).

The therapy is applied across domains where additional symptomatic support is needed, such as managing cancers that are relapsed or refractory to prior treatments, and is crucial in the adjuvant setting to manage the risk of recurrence after initial surgery. The goal is to assist with supporting overall well-being during symptomatic phases. The therapy may assist with maintaining functional stability during symptomatic periods.

Quick Fact: Relief for Cancer Progression

The medication is applied in situations where symptoms that interfere with daily functioning are driven by active, spreading malignancy, providing support that helps ease the overall symptom burden associated with widespread disease.

Regulatory References

European Medicines Agency ( EMA) Product Information

Eligibility and Restrictions for Use

Officially Documented Eligibility Profile

Regulatory authorities define eligibility for Pembrolizumab (Keytruda) based on patient status, age, and specific pre-existing conditions.

Eligibility Scope

Populations for whom use is contraindicated (Prohibited): Patients with known hypersensitivity to the active substance (pembrolizumab) or any excipients in the formulation are formally prohibited from use. A similar contraindication applies to excipients in the subcutaneous formulation.
Populations for whom use is not recommended: Use is explicitly not recommended for patients with Primary Mediastinal Large B-Cell Lymphoma (PMBCL) who require urgent cytoreductive therapy. It is also not recommended in patients with multiple myeloma when combined with a thalidomide analogue plus dexamethasone, outside of controlled trials.
Age-Related Eligibility: The medicine is approved for adults across most indications. Pediatric use is established for patients 3 years and older (e.g., Classical Hodgkin Lymphoma) and 12 years and older (e.g., melanoma), varying by indication. Use in certain older adult cohorts is limited by insufficient data.
Conditional and Restricted Use: The official label states the drug has not been studied in patients with severe renal impairment or moderate or severe hepatic impairment. For NSCLC with EGFR or ALK genomic aberrations, eligibility is conditional upon demonstrating disease progression on prior targeted therapy. Use in pregnant females is restricted as it may cause fetal harm, requiring effective contraception for females of reproductive potential.

What should I know about interactions with other medicines?

Interaction scope

Medicinal product categories with documented interactions: Systemic Immunosuppressive Agents, Live Attenuated Vaccines, and Thalidomide Analogues.

Specific interacting medicines (if explicitly listed): Thalidomide Analogues (such as lenalidomide) in combination with dexamethasone.

Mechanistic basis of interactions (only if stated in label): The drug’s structure as a large monoclonal antibody results in no documented metabolic interactions via the cytochrome P450 (CYP) enzyme system or drug transporters. Pharmacodynamic interactions involve the potential for systemic immunosuppressive agents to interfere with the drug’s T-cell activating mechanism.

Timing-based interaction rules (if applicable): Co-administration with live attenuated vaccines is prohibited during treatment and for a specific period after the final dose.

Population-specific interaction notes (if applicable): Severe and fatal complications, including hepatic veno-occlusive disease (VOD) and acute graft-versus-host disease (GVHD), can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after treatment.

Interaction-related restrictions: Co-administration with a thalidomide analogue and dexamethasone for multiple myeloma is not recommended outside of controlled clinical trials. Live attenuated vaccines are formally contraindicated.

Interaction classifications (high-level)

Interaction severity classification (as defined in official documents): Combinations with Live Attenuated Vaccines and the thalidomide analogue/dexamethasone regimen are classified as high clinical significance, requiring avoidance or restriction. Potential pharmacodynamic interference exists with systemic corticosteroids, though their use is permitted for replacement therapy or for managing immune-mediated adverse reactions.

Connection to the overall interaction profile (2–4 sentences): The official interaction profile is defined by the drug's limited involvement with common metabolic pathways, meaning typical small-molecule drug interactions are not documented. Instead, the focus is on pharmacodynamic constraints related to immune system modulation, imposing restrictions on specific classes of immunosuppressants and vaccines. The profile is further structured by formal warnings against specific high-risk drug combinations and procedural constraints for allogeneic HSCT patients.

Mechanism of Action

Targeted Blockade of the PD-1 Immune Checkpoint

The core mechanism relies on Pembrolizumab, a humanized monoclonal antibody that functions as a highly specific antagonist of the Programmed Death Receptor-1 (PD-1) protein on T-cells. By binding to PD-1, the antibody physically blocks the receptor from engaging with its inhibitory ligands, PD-L1 and PD-L2, often found on the surface of cells expressing these ligands. This interruption removes the physiological inhibitory signal on the T-cell, which is central to modulating T-cell function and capability.

Systemic Reversal of T-cell Inhibition

The blockade of the PD-1 receptor triggers a crucial mechanistic cascade. The removal of the chronic inhibitory signal allows previously suppressed or "exhausted" Cytotoxic T-lymphocytes (CTLs) to regain functionality. This results in the T-cells proliferating, maturing, and activating their cytolytic (cell-killing) effector function. The resulting physiological effect is the restoration of a systemic, T-cell-mediated immune response, resulting in the modulation of the T-cell state and the initiation of cytotoxic activity.

Auxiliary Mechanism for Subcutaneous Delivery

The subcutaneous formulation includes the enzyme Berahyaluronidase alfa-pmph to facilitate the systemic distribution of the large monoclonal antibody. This enzyme achieves its effect by temporarily degrading hyaluronan, a key structural component of the extracellular matrix. This auxiliary mechanism temporarily increases the local tissue permeability, which is required to increase the local dispersion and subsequent systemic absorption of the antibody, thus enabling the PD-1 blockade to occur via an alternative route.

Dosage and Administration Information

Keytruda (pembrolizumab) is administered as an intravenous (IV) infusion under the supervision of a healthcare professional. It is not a take-home, oral, or self-administered medication.

Official Dosing and Frequency

The recommended dosing schedule is either 200 mg every 3 weeks or 400 mg every 6 weeks for all approved adult indications. Both regimens are administered as an IV infusion over 30 minutes.

For most pediatric patients, including those with classical Hodgkin lymphoma (cHL) or microsatellite instability-high (MSI-H) solid tumors, the dose is 2 mg/kg (up to a maximum of 200 mg) every 3 weeks. Treatment duration varies by indication, such as up to 12 months for adjuvant melanoma and up to 24 months for some non-small cell lung cancer (NSCLC) regimens, or until disease progression or unacceptable toxicity.

Preparation and Administration Steps

Preparation: Aseptic technique is mandatory. Keytruda is supplied as a solution for injection or a lyophilized powder requiring reconstitution with sterile water (followed by gentle swirling—do not shake the vial). The required dose is then withdrawn and diluted into an IV bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection, ensuring the final concentration is between 1 mg/mL and 10 mg/mL.

Procedure: The diluted solution must be administered via an IV line fitted with a sterile, non-pyrogenic, low-protein binding 0.2 to 5 micron in-line or add-on filter. No other medications should be co-administered through the same line.

Missed Dose: No dose reductions are recommended for Keytruda. Treatment modifications involve withholding or permanent discontinuation of the drug to manage specific adverse reactions.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Keytruda

This overview summarizes the clinical evaluation conducted to evaluate Keytruda ( Pembrolizumab), focusing only on the structure of the studies, the outcomes that were measured, and what remains uncertain according to regulatory documents and scientific literature. The information provided here is strictly descriptive and is not a substitute for professional medical advice.

Evidence for Major Solid Tumors (Melanoma and NSCLC)

Research for melanoma and Non-Small Cell Lung Cancer (NSCLC) relies primarily on large Randomized Controlled Trials (RCTs). These studies were designed to evaluate the therapy alone or in combination with chemotherapy, monitoring outcomes like Overall Survival (OS) and Progression-Free Survival (PFS). Trials reported that differences in these survival measurements were observed between the group that received the study medicine and the comparator groups. For the adjuvant setting (treatment after surgery), studies examined Disease-Free Survival (DFS). Long-term follow-up data, sometimes extending beyond five years, describes measurements observed over extended periods in patient subsets.

Evidence for Specific Tumors and Markers

For conditions like Urothelial Carcinoma and marker-specific tumors such as Microsatellite Instability-High (MSI-H) solid tumors and Classical Hodgkin Lymphoma (cHL), the evidence often incorporates non-randomized, multi-cohort trials. These studies typically monitored Objective Response Rate (ORR) and Duration of Response (DOR). In these areas, initial regulatory approvals were sometimes based on these intermediate measures, and confirmatory trials are ongoing to provide more definitive long-term survival data.

Study Durations and Patient Groups

Studies have explored measurements observed over time by including extended follow-up periods that monitored patients for years after initial treatment. However, the evidence landscape includes some limitations. Data for certain patient groups remain insufficient, particularly regarding research on the pediatric central nervous system cancer population. Furthermore, the relationship between molecular markers and study outcomes was not uniform across all trials. Research highlights that evidence quality varies across studies, and that some approvals relied on short-term follow-up durations and surrogate endpoints.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Keytruda (FAQ)

Q: How long does the IV Keytruda infusion take?

Official product information notes that the intravenous infusion of Keytruda is administered over a period of approximately 30 minutes. This duration is generally consistent across all approved dosing schedules.

Q: What are the signs or symptoms of a serious infusion-related reaction?

Regulatory safety information indicates that reported signs and symptoms associated with infusion-related reactions may include chills or shaking, itching, dizziness, rash, flushing, fever, difficulty breathing, and back pain. Patients should report any unusual symptoms during or after the infusion to their healthcare provider immediately.

Q: Is Keytruda used to treat other cancers beyond melanoma and NSCLC?

Yes, official indications show that Keytruda is approved for the treatment of numerous other cancers. These indications include classical Hodgkin lymphoma (cHL), urothelial carcinoma, head and neck squamous cell carcinoma (HNSCC), and cancers with specific markers such as Microsatellite Instability-High (MSI-H) solid tumors.

Q: What happens if a patient misses a scheduled dose?

Official regulatory documents detail procedures for modifying or discontinuing treatment specifically to manage adverse reactions. However, the label does not provide universal instructions on how to handle a logistical missed dose. Any changes to the scheduled treatment, including how to handle a missed dose, should be addressed by the treating healthcare team.

Q: Can a patient with severe kidney disease be treated with this medicine?

Studies and official product information indicate that Keytruda has not been studied in patients with severe renal (kidney) impairment. This means that data to fully assess the safety and effectiveness of the drug specifically in patients with severe renal impairment are limited or not available.

Q: What are the preparation steps before the Keytruda infusion?

Before the infusion is administered, a healthcare professional prepares the solution by withdrawing the required dose from the vial. This is then diluted in an intravenous bag of either 0.9% Sodium Chloride or 5% Dextrose to achieve the final therapeutic concentration.

Q: What is the role of the 0.2 to 5 micron filter during the infusion?

The administration procedure requires the diluted Keytruda solution to pass through a sterile, non-pyrogenic, low-protein binding filter. This filter is used as part of the standard administration procedure to help maintain the quality and sterility of the medicine during infusion.

Q: What are the rules for proper handling and disposal of unused Keytruda?

Unused portions of the medication and related waste materials must be discarded following specific local requirements. Due to the nature of the medication, any unused portion and related waste must be managed according to special local protocols for pharmaceutical disposal.

How should Keytruda be stored and disposed of?

The storage and disposal of Keytruda (pembrolizumab) are subject to specific regulatory conditions to maintain the stability of this preservative-free solution.

Official Storage Conditions

Product Form	Temperature Range	Protection Requirement
Unopened Vial	Refrigeration: 2 C to 8 C	Store in original carton to protect from light; Do not freeze
Diluted Solution	Room temp (le25 C) or Refrigerated	Do not shake; inspect visually before use

Stability and Disposal Rules

The total stability of the diluted solution (100 mg/4 mL) must not exceed 6 hours at room temperature or 96 hours if stored under refrigeration (2 C to 8 C). The storage time includes the duration of the infusion.

All unused portions remaining in the vial and any expired product must be discarded. Disposal of unused medicine and waste materials must be carried out in accordance with local requirements. The product must be stored out of the reach and sight of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.